A Study of TRK-950 When Used in Combination With Ramucirumab and Paclitaxel in Patients With Gastric Cancer

This study will assess the efficacy, safety, optimal dose and ADA and NAbs development of TRK-950 at two separate dose levels in combination with ramucirumab and paclitaxel (RAM+PTX) as compared with RAM + PTX treatment alone in participants with gastric or gastro-esophageal junction (GEJ) adenocarcinoma.

Trial Details

NCT ID
NCT06038578
Phase
PHASE2
Sponsor
Toray Industries, Inc
Status
RECRUITING
Cancer Type
Gastric Cancer
Interventions
  • TRK-950
  • Ramucirumab
  • Paclitaxel
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Irvine, California, United States|33.66946,-117.82311
  • Santa Monica, California, United States|34.01949,-118.49138
  • Arlington, Texas, United States|32.73569,-97.10807
  • Bedford, Texas, United States|32.84402,-97.14307

Key Eligibility Criteria

  • Histologically or cytologically confirmed metastatic, or locally advanced and unresectable gastric or GEJ adenocarcinoma.
  • The patient is eligible to receive Ramucirumab + Paclitaxel.
  • Documented objective radiographic or clinical disease progression (e.g., any new or worsening malignant effusion documented by ultrasound examinati…
  • First treatment for metastatic disease or locally advanced disease without experiencing adjuvant / neo-adjuvant treatment, which progressed during …

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Gastric Cancer Trials on Trialify →